Shomit Mansur, PhD

 Led analytical method development and validation for assay, dissolution, and impurity testing for generic drugs and APIs, reducing development timelines by 20%.  Designed and optimized sample preparation protocols (SPE, LLE, hydrolysis, magnetic bead separation), improving recovery rates by 35% and enhancing sensitivity of low-dose formulations.  Contributed to successful batch release and stability testing by performing routine QC under strict cGMP, GLP, and USP standards.  Authored and executed SOPs and validation reports; supported regulatory documentation for internal audits and external agency inspections.  Performed instrument troubleshooting, maintenance, and calibration (LC-MS, GC-MS, UPLC, FTIR), reducing lab downtime by 40%.  Collaborated with R&D and QC teams to support seamless method transfer, ensuring operational readiness for scale-up.

 Designed and executed research projects on nanoparticle-based drug discovery platforms; secured 50K in research funding.  Developed and optimized LC-MS protocols to characterize proteins and small-molecules; validated analytical performance metrics.  Performed analytical method development using RP-HPLC, SEC, and IEX to resolve and analyze complex biomolecular formulations.  Conducted ELISA and Western blot to assess protein expression; performed nanoparticle uptake tracking via confocal microscopy to validate targeted release.  Published two first-author peer-reviewed articles, wrote technical reports, and presented results at national and international scientific conferences.  Mentored 5+ researchers in nanoparticle characterization, cell sorting, data representation, and instrument troubleshooting.

Dissertation Topic "Developing a novel drug screening nanoplatform to detect potential drug leads from complex matrices"  Researched to establish a uniform synthesis method to prepare our magnetic drug screening nanoplatform of desired size, shape, uniformity and surface chemistry.  Prepared protocols for cell culture and isolate cell membranes and then encapsulate nanoparticles to develop drug screening nanoplatform with immobilized transmembrane receptors on surface.  Executed a conventional magnetic ligand fishing drug screening approach to identify selective transmembrane receptor binders and identify their anticancer effects via in vitro cell based assays.